A real-world cost-effectiveness analysis demonstrates that introducing Plerixafor to improve mobilization in multiple myeloma patients who behave as poor mobilizers is cost-effective considering the whole mobilization and transplant procedure

R. Touzani,A-M Stoppa,C. Lemarie, M. Debals-Gontier,B. Calmels,R. Bouabdallah,A. Granata, A-G L. Corroller-Soriano,C. Chabannon

BONE MARROW TRANSPLANTATION(2017)

引用 0|浏览3
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要